CD274 and non-small cell lung carcinoma: In addition to its role in measuring the residual benefit of PD-1/PD-L1 blockade, the TGR could also be investigated as a predictive factor for PPS in the setting of PD after DCB in future studies in the same way as what has been previously performed at the baseline of immunotherapy in NSCLC [17,18].